MetaCap

Amarin (AMRN) vs Capricor Therapeutics (CAPR)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Capricor Therapeutics (CAPR) has outperformed Amarin (AMRN) over the past year, gaining 32.0% versus a loss of 35.5%. Over five years, CAPR leads with a +122.6% price change compared with -85.5% for AMRN. Amarin is the larger company by market cap ($444.4 million vs $441.3 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AMRN-35.47%CAPR+32.00%
+542%+240%-63%
Nov 21, 20251 yearNov 20, 2026
AMRN-86.45%CAPR+127.93%
+1012%+435%-142%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AMRN versus CAPR key metrics
MetricAMRNCAPR
Share price$10.57$7.59
Market cap$444.39M$441.30M
1-day change-6.13%+0.80%
YTD return-24.28%-73.70%
1-year return-35.47%+32.00%
5-year return-85.48%+122.58%
Forward P/E10.79—
EPS (TTM)$-0.80$-2.65
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$213.65M$0
Revenue growth (YoY)-6.55%-100.00%
Net income (latest FY)$-38.80M$-105.04M
Gross margin56.57%—
Operating margin-23.48%—
Net margin-18.16%—
52-week high$17.31$40.37
52-week low$10.56$2.96
Distance from 52-week high-38.94%-81.20%
Analyst consensusnonebuy
Avg. price target upside+22.99%+259.03%
Average volume79.50K4.73M
Shares outstanding42.04M58.14M
Employees80231
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CAPR has outperformed AMRN by 67.5 percentage points over the past year.
  • Amarin grew revenue faster in its latest fiscal year (-6.55% vs -100.00%).

About Amarin

AMRN stock →

Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.

Health Care · Biotechnology: Pharmaceutical Preparations · 80 employees

About Capricor Therapeutics

CAPR stock →

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD.

Health Care · Biotechnology: Pharmaceutical Preparations · 231 employees

AMRN vs CAPR FAQ

Which is bigger, Amarin or Capricor Therapeutics?

Amarin (AMRN) is larger, with a market capitalization of $444.39M compared with $441.30M for Capricor Therapeutics (CAPR).

Which stock has performed better over the past year, AMRN or CAPR?

CAPR returned +32.00% over the past 12 months, compared with -35.47% for AMRN (price return, excluding dividends). Past performance does not predict future results.

Are Amarin and Capricor Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons